Enveric Biosciences has announced the issuance of a new U.S. patent (USPTO Number 12,187,679) covering a novel family of molecules with potential applications in treating sleep and central nervous system $(CNS)$ disorders. This patent enhances the company's intellectual property portfolio and includes selective melatonin receptor-binding compounds, which could be used to target sleep disorders. Among the covered molecules are potential MT1-selective agonists, suggesting promise for innovative sleep therapeutics. The patent further supports Enveric's CNS-focused strategy, targeting high-value therapeutic markets.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.